Trial of Aromatase Inhibition in Lymphangioleiomyomatosis (TRAIL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01353209|
Recruitment Status : Completed
First Posted : May 12, 2011
Last Update Posted : August 26, 2015
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Lymphangioleiomyomatosis||Drug: Letrozole Drug: Placebo||Phase 2|
Lymphangioleiomyomatosis, or LAM, is an uncommon, progressive, cystic lung disease that predominantly affects young women. Pulmonary parenchymal changes consistent with LAM are found in about one third of women with tuberous sclerosis complex (TSC), an autosomal dominant tumor suppressor syndrome. LAM also occurs in a sporadic form that is not associated with germ line mutations in TSC genes. Recent evidence that recurrent LAM after lung transplantation results from seeding of the graft from a remote source and suggests a metastatic mechanism for the disease.
Since LAM occurs almost exclusively in women, and exposure to estrogen either exogenously or during pregnancy can exacerbate LAM, estrogen suppression might be expected to prevent or delay progression of disease. In preclinical studies, estrogen induces the growth of TSC2-deficient cells and tumor cells derived from LAM patients. In a xenograft model of lymphangioleiomyomatosis presented by Dr. Yu at the 2008 LAM Research Meeting, estrogen promoted the pulmonary metastases of tuberin-deficient ELT3 cells (TSC2-deficient rat uterine leiomyoma cells) in female ovariectomized CB-17-scid mice, while the estrogen inhibitor fulvestrant completely blocked estrogen-promoted pulmonary metastases. This work was recently published.
Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis)(14). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)diben-zonitrile.
In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||September 2014|
2.5 mg daily for twelve months
Other Name: Femara
|Placebo Comparator: Placebo||
sugar pill given daily for twelve months
- The effect on Forced Expiratory Volume in one second [ Time Frame: twelve months ]
- Other measures of pulmonary function [ Time Frame: twelve months ]FVC, DLCO, TLC,RV, FRC, 6MWT
- Quality of life measures [ Time Frame: twelve months ]Quality of Life, dyspnea and fatigue, functional performance
- Serum VEGF-D [ Time Frame: twelve months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
All patients at least must have a diagnosis of pulmonary lymphangioleiomyomatosis as defined by one of the following:
- CT chest compatible with LAM and a biopsy or cytology consistent withLAM.
- CT chest consistent with LAM in the setting of tuberous sclerosis, renal angiomyolipomata, cystic abdominal lymphangiomas, or chylous effusion in the chest or abdomen , or serum VEGF-D > 800 pg/uL.
- All patients must have a post bronchodilator FEV1 ≤80% predicted or DLCO ≤70% predicted or RV≥120% predicted
All patients must be postmenopausal females as defined by one of the following:
- Prior bilateral oophorectomy or bilateral ovarian irradiation.
- If age greater than 55 years, no menstrual period for 12 months or longer.
- If age 55 years or younger, must have an estradiol level in the postmenopausal range in the absence of current use of progestational agents.
- If still premenopausal, may enter if rendered medically postmenopausal on clinical grounds with the use of gonadotropin releasing hormone (e.g. leuprolide), as long as serum estradiol, FSH, and LH are in the postmenopausal range
- Patients with osteopenia or osteoporosis must be receiving appropriate treatment for their osteoporosis or osteopenia at entry into this study.
Patients must have adequate hematologic and hepatic function as defined by the following at the time of randomization.:
- Neutrophils > 1500/mm3 and platelets > 100,000/mm3
- Bilirubin < 1.25 X upper limit of normal
- SGPT (ALT) and SGOT (AST) < 2.5 X upper limit of normal
- Known allergy to letrozole
- Inability to comply with pulmonary function tests or follow up visits.
- Treatment with investigational agents within 30 days
- Hormonal therapy (e.g. estrogen, progestin, LHRH agonists or antagonists, estrogen receptor blockers, estrogen receptor down regulators, aromatase inhibitors) within 30 days month of registration
- Medical or psychiatric conditions that would interfere with the ability to provide informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01353209
|United States, California|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|United States, Florida|
|Jacksonville, Florida, United States, 32224|
|University of Miami|
|Miami, Florida, United States, 33136|
|United States, Georgia|
|Emory University School of Medicine|
|Atlanta, Georgia, United States, 30322|
|United States, Illinois|
|Loyola University Medical Center|
|Maywood, Illinois, United States, 60153|
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|United States, Ohio|
|University of Cincinnati|
|Cincinnati, Ohio, United States, 45267|
|Cleveland, Ohio, United States, 44195|
|United States, Washington|
|Minor and James|
|Seattle, Washington, United States, 98122|
|Principal Investigator:||Francis X McCormack, MD||University of Cincinnati|
|Responsible Party:||Francis McCormack, Pulmonary Director, University of Cincinnati|
|Other Study ID Numbers:||
|First Posted:||May 12, 2011 Key Record Dates|
|Last Update Posted:||August 26, 2015|
|Last Verified:||August 2015|
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Immune System Diseases
Steroid Synthesis Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs